Sanofi's push to concentrate its Consumer Healthcare portfolio on priority categories sees it offload two OTC brands in Germany and Austria. Meanwhile, new Sanofi CEO Paul Hudson has spoken about his intention to review the firm's plans in the OTC market.
Sanofi has divested two OTC brands to Italy’s Angelini SPA in a deal worth €47m ($51m). The French firm signaled earlier this year that it would continue to rationalize its Consumer Healthcare portfolio to focus its efforts around a number of priority brands and categories. (Also see "Sanofi Plans Further Consumer Health Divestments As It Reports Slow Start To Year" - HBW Insight, 29 April, 2019.)
Angelini has picked up the BoxaGrippal (ibuprofen/pseudoephedrine) cold and flu brand and the Heumann range of medicinal teas indicated to...
Explore how consumer health is evolving. On the go.
David Ridley hosts in-depth conversations with industry leaders.
In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.